Ambulatory Care Pharmacy | NYU Langone Health
The pharmacists at NYU Langone’s Ambulatory Care Pharmacy make getting a prescription filled quick, easy, and convenient.
Amyloidosis Program | NYU Langone Health
Experts in the Amyloidosis Program at NYU Langone’s Perlmutter Cancer Center specialize in the diagnosis and treatment of amyloidosis.
Amyotrophic Lateral Sclerosis | NYU Langone Health
Doctors at NYU Langone provide an accurate diagnosis and ongoing support to people with ALS and their families.
An Adaptive Phase 2a/2b Randomized Double-Blind Placebo-Controlled Study of LY3871801 in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis
This study is being done to see how safe an investigational drug is and how well it will work to help people with moderately to severely active rheumatoid arthritis (RA).
An Evaluation of Home Urinalysis Testing for Systemic Lupus Erythematosus (SLE) Patients at Elevated Risk for Developing Lupus Nephritis: A Pilot Stage and Randomized Controlled Study
Pilot Study: Feasibility, acceptability, and adaptation. We will produce a teaching video for home-based proteinuria testing that will instruct patients on how to collect a sample and evaluate the home colorimetric dipsticks (only protein, Siemens Albutrix).The urinalysis video planned, which will simply instruct the patients how to line up the dipsticks with the single protein color chart and match the color most closely corresponding to their urine. A scoring system will be explained, such that the color matching will be assigned as follows: negative = 1, trace = 2, +300 (.300g/l) = 3, 1.000g/l = 4, 3.000g/l = 5, 10.000g/l = 6.Following informed consent at their clinic visit, 18 participating patients will view the educational video, with available subtitles in all three languages (i.e., English, Spanish and Mandarin. The patient will have sufficient dipsticks to test the first morning void once weekly for a year (with weekly reminders via a text protocol) unless earlier intervention is required. For reporting the weekly score, the patient will be instructed to respond to the text they receive on the morning of the weekly dipstick check and enter the number corresponding to the color matching the dipstick, and indicate “period” if menstruating. If the score provided by the patient is 3 or greater for two consecutive weeks, the texting program will be programmed to alert the coordinator to call the patient and ask the patient come to the local laboratory for a formal UPCR. A UPCR of 0.5 or greater would trigger an immediate SOC visit with Drs. Buyon, Saxena, Belmont, or Izmirly. We will be using the HIPAA-compliant texting platform, SlickText, for patient communication. Participants will be able to send STOP message to opt out, and the only information included is their phone number. Additionally, they will be able to send TEAM message to receive a call from the coordinator if they encounter any difficulties. Each participant will receive texts in their preferred language. Feasibility for Stage 1 will be assessed quantitatively by the number of patients approached for the evaluation versus number willing to participate, with 70% participating as considered feasible. Acceptability will be determined if =80% of participants respond that they are at least moderately satisfied, using a brief Client Satisfaction Questionnaire. Data on adherence and implementation feasibility will be captured via SlickText (number of weeks returning a dipstick value divided by overall weeks, accommodating menstruation when urinalysis may not be completed, although patients will be instructed to collect the urine and record their period). Adherence of 75% will be considered successful. Further, we will aim to clinically validate the scores reported by patients who have a scheduled standard-of-care visit preferably on the same day as the weekly morning dipstick scoring is done; we will attempt to assure that patient score readings of 1 or 2 correspond to UPCR < 0.3. If we find errors, we will coach the patient and check their supply of dipsticks for deterioration. At the middle and end of the first year of the protocol, we will conduct debriefing interviews to evaluate the personal experiences and satisfaction with the intervention and modify the protocol accordingly. Clinical Trial To Follow: Implement a larger randomized controlled trial (RCT) among all eligible in the NYU Lupus Cohort (160 participating patients). Patients will be enrolled and randomized (1:1) to home testing intervention in addition to standard of care or standard of care only. Patients who have a scheduled standard-of-care visit preferably on the same day as the weekly morning dipstick scoring is done; we will attempt to assure that patient score readings of 1 or 2 correspond to UPCR < 0.3. The primary outcome will be that has a clinical indication for a kidney biopsy (UPCR 0.5 regardless of either de novo or relapsed disease), whether or not the patient actually undergoes the procedure.
An observational multi-center study to validate outcome measures for future clinical trials of Multiple System Atrophy (MSA)
The purpose of this research study is to develop and validate new methods to measure if a potential drug being tested in future clinical trials of patients with multiple system atrophy (MSA) is effective. These methods include a scale or questionnaire (“clinical outcome assessment” or COA), brain neuroimaging (magnetic resonance imaging or MRI) and biochemical biomarkers (blood or cerebrospinal fluid (CSF) samples).
An Open-Label Multi-Center Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcomes
This is an open label, multi-center, retrospective and prospective clinical study. Patients who are to undergo shoulder arthroplasty may be screened for participation. Likewise, patients who have previously undergone shoulder arthroplasty with the Equinoxe®, or other arthroplasty systems, may be screened for enrollment. This study may include patients from multiple centers, both US and international, undergoing hemi- or total shoulder joint replacement. Patients will be screened for enrollment based upon the inclusion and exclusion criteria described in the protocol.
AN OPEN-LABEL MULTICENTER PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-2100 IN PATIENTS WITH RECURRENT ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCRCC)
This is a study seeing if a new cellular medicine called AB-2100, a logic-gated CAR T cell targeting PSMA and Ca-IX, is effective for adult patients with a specific type of advanced kidney cancer called clear-cell renal cell carcinoma (ccRCC). The study team wants to the safety and anti-cancer effectiveness of this medicine. Patients will try different doses of AB-2100 in the first part of the study, and once they figure out the right amount that has tolerable side effects, more patients will receive the treatment in the second part. The study is split into different steps for each patient, like checking if they're a good fit for the study, getting cell samples from the patient, preparing the body for treatment, receiving the medicine, and then seeing how things go afterward concerning treatment.
AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This is a study of a drug called LOXO-435 for patients with advanced solid tumors, specifically focusing on metastatic urothelial cancer (mUC) that has a change in a gene called FGFR3. The study will be conducted in two phases. Phase 1a is the first part and will test different doses of LOXO-435 to determine its safety, how well it is accepted by the patient's body, how the body processes it (pharmacokinetics), and its initial effectiveness. This phase will include patients with any type of solid tumor that has an alteration in the FGFR3 gene or its related proteins. The goal is to find the recommended dose for the next phase. Phase 1b is the second part and will involve four groups of patients receiving the recommended dose from Phase 1a. These groups will include patients with urothelial cancer, either as a single treatment or in combination with pembrolizumab (another drug), as well as patients with other types of advanced solid tumors who will receive LOXO-435 alone. The purpose is to evaluate the effectiveness and safety of LOXO-435 in these specific patient groups.
An Open-label Phase 1 Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
This study is testing a NT-112, a type of cellular therapy, in patients with advanced cancer, such as lung, pancreatic, or colorectal cancer, who have a specific genetic change called KRAS G12D. The study team wants to see if the medicine has few side effects and is effective in treating the cancer. They will try different amounts of the medicine to find thehighest dose that patients can handle without severe side effects. The researchers will carefully follow a plan to decide how much medicine each patient will get. The study team will keep a close eye on any side effects. The study has different periods, like screening, where they check if people meet the criteria, enrollment, treatment, and follow-up. Patients will go through various tests before joining the study, and the researchers will collect information about safety, effectiveness, and other factors.